Canine Hip Dysplasia: Reviewing the Evidence for Nonsurgical Management

Seattle Veterinary Specialists, Kirkland, WA.
Veterinary Surgery (Impact Factor: 0.99). 12/2011; 41(1). DOI: 10.1111/j.1532-950X.2011.00928.x
Source: PubMed

ABSTRACT OBJECTIVE: To systematically review the evidence available for nonsurgical management of hip dysplasia (HD). STUDY DESIGN: Literature review. METHODS: Databases (Pubmed, Veterinary Information Network) were searched for clinical studies on nonsurgical management of HD in dogs. The evidence in each study was reviewed and assigned a score (I-IV) based on previously reported levels of evidence. RESULTS: Fourteen articles were identified that met the inclusion criteria, including 3 Level IV, 4 Level III, and 7 Level II studies. Methods of nonsurgical management reviewed included: activity restrictions, weight management, acupuncture, modulation of joint disease by polysulfated glycosaminoglycans, mesenchymal stem cell therapy, and extra corporeal shock wave therapy. CONCLUSION: Weight management is an effective and important component of managing dogs with HD and associated osteoarthritis. Techniques that modulate the progression of joint disease may also be beneficial for treating dogs with HD. Further studies are needed to investigate other methods of managing HD such as hydrotherapy and physical rehabilitation.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Current research indicates that exogenous stem cells may accelerate reparative processes in joint disease. However, no previous studies have evaluated whether bone marrow cells (BMCs) target the injured cranial cruciate ligament (CCL) in dogs. The objective of this study was to investigate engraftment of BMCs following intra-articular injection in dogs with spontaneous CCL injury. Autologous PKH26-labeled BMCs were injected into the stifle joint of eight client-owned dogs with CCL rupture. The effects of PKH26 staining on cell viability and PKH26 fluorescence intensity were analyzed in vitro using a MTT assay and flow cytometry. Labelled BMCs in injured CCL tissue were identified using fluorescence microscopy of biopsies harvested 3 and 13 days after intra-articular BMC injection. The intensity of PKH26 fluorescence declines with cell division but was still detectable after 16 days. Labelling with PKH26 had no detectable effect on cell viability or proliferation. Only rare PKH26-positive cells were present in biopsies of the injured CCL in 3/7 dogs and in synovial fluid in 1/7 dogs. No differences in transforming growth factor-β1, and interleukin-6 before and after BMC treatment were found and no clinical complications were noted during a 1 year follow-up period. In conclusion, BMCs were shown to engraft to the injured CCL in dogs when injected into the articular cavity. Intra-articular application of PKH26-labeled cultured mesenchymal stem cells is likely to result in higher numbers of engrafted cells that can be tracked using this method in a clinical setting.
    The Veterinary Journal 09/2014; 202(3). DOI:10.1016/j.tvjl.2014.08.031 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells isolated from adipose tissue show great therapeutic potential in veterinary medicine, but some points such as the use of fresh or cultured cells and route of administration need better knowledge. This study aimed to evaluate the effect of autologous stromal vascular fraction (SVF, n = 4) or allogeneic cultured adipose-derived stem cells (ASCs, n = 5) injected into acupuncture points in dogs with hip dysplasia and weak response to drug therapy. Canine ASCs have proliferation and differentiation potential similar to ASCs from other species. After the first week of treatment, clinical evaluation showed marked improvement compared with baseline results in all patients treated with autologous SVF and three of the dogs treated with allogeneic ASCs. On days 15 and 30, all dogs showed improvement in range of motion, lameness at trot, and pain on manipulation of the joints, except for one ASC-treated patient. Positive results were more clearly seen in the SVF-treated group. These results show that autologous SVF or allogeneic ASCs can be safely used in acupoint injection for treating hip dysplasia in dogs and represent an important therapeutic alternative for this type of pathology. Further studies are necessary to assess a possible advantage of SVF cells in treating joint diseases.
    08/2014; 2014:391274. DOI:10.1155/2014/391274
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: One hundred and five Labrador dogs were distributed randomly into two groups with the aim of studying the number of dogs that develop elbow dysplasia when treated with an oral supplement compared to dogs without treatment, and the efficacy of treatment once the illness was diagnosed. The supplement (Hyaloral®, Pharmadiet) contained hyaluronic acid, hydrolysed collagen, glucosamine, chondroitin sulphate and gamma oryzanol. Clinical evaluation of elbow joints was completed at months 3, 6, 12 and 20, by orthopaedic controls, radiographs, serologic and blood analysis, and veterinarian evaluations of symptoms of dysplasia. Any side effects were recorded. Results revealed that 33.3% of dogs in the control group developed radiographic evidence of elbow dysplasia compared to 18.5% in treated group. Symptoms of dysplasia at 12 months showed differences between treated (12.5%) and control (61.5%); being significantly different at 20 months (p<0.05). Data analysis of lameness, movement and swelling of elbows revealed differences between groups after 12 months; improving significantly at the last visit in treated group (p<0.05). No adverse events were reported. In conclusion, oral treatment with Hyaloral® may have a potential cumulative action in the protection against dysplasia and improves symptoms of elbow dysplasia significantly.
    Journal of Veterinary Science 09/2014; 15(4). DOI:10.4142/jvs.2014.15.4.569 · 1.14 Impact Factor


Available from